Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study
Interventions: DRUG: Herzuma
Sponsor: Gangnam Severance Hospital